Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LXEO
stocks logo

LXEO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.307
-60.85%
--
--
-0.377
-61.95%
--
--
-0.393
-41.89%
Estimates Revision
The market is revising No Change the revenue expectations for Lexeo Therapeutics, Inc. (LXEO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 81.08%.
EPS Estimates for FY2025
Revise Downward
down Image
-22.67%
In Past 3 Month
Stock Price
Go Up
up Image
+81.08%
In Past 3 Month
Wall Street analysts forecast LXEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXEO is 19.57 USD with a low forecast of 13.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast LXEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXEO is 19.57 USD with a low forecast of 13.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.090
sliders
Low
13.00
Averages
19.57
High
30.00
Current: 9.090
sliders
Low
13.00
Averages
19.57
High
30.00
Cantor Fitzgerald
NULL -> Overweight
initiated
$19
2025-11-20
Reason
Cantor Fitzgerald
Price Target
$19
2025-11-20
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with an Overweight rating and $19 price target.
Cantor Fitzgerald
Overweight
initiated
$19
2025-11-20
Reason
Cantor Fitzgerald
Price Target
$19
2025-11-20
initiated
Overweight
Reason
Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with an Overweight rating and $19 price target. Lead asset LX2006 is an AAVrh10-based gene therapy for Friedreich's ataxia cardiomyopathy in pre-pivotal development, and Lexeo is also developing LX2020 as an AAVrh10-based gene therapy in PKP2 arrhythmogenic cardiomyopathy, the analyst tells investors in a research note. The firm applauds management's approach to be transparent with frequent, quarterly safety updates, and thinks Lexeo could prove itself to be a leading cardiac-gene therapy company.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$13
2025-11-03
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$13
2025-11-03
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $13 price target on Lexeo Therapeutics, saying Monday's selloff looks "highly unwarranted" given the company's data integrity and forward-aligned FDA dialogue. Lexeo's concurrent-control design is exactly what the modern FDA wants to see, not what it is pushing back on, the analyst says, adding that Lexeo's alignment was reached under a new guard, positioning it firmly within today's regulatory expectations. The firm also noted that it views Lexeo as one of the few gene-therapy developers that pre-emptively designed to the FDA's post-reorganization, post-Marks standard for evidence generation, and that the roughly 10% selloff reflects confusion between the regulatory tightening and regulatory alignment and creates a clear buying opportunity.
H.C. Wainwright
Buy
downgrade
$15 -> $13
2025-10-21
Reason
H.C. Wainwright
Price Target
$15 -> $13
2025-10-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Lexeo Therapeutics to $13 from $15 and keeps a Buy rating on the shares. The firm cites share dilution from the most recent equity raise for the target cut.
Leerink
Mani Foroohar
Outperform
to
Outperform
downgrade
$20 -> $18
2025-10-17
Reason
Leerink
Mani Foroohar
Price Target
$20 -> $18
2025-10-17
downgrade
Outperform
to
Outperform
Reason
Leerink analyst Mani Foroohar lowered the firm's price target on Lexeo Therapeutics to $18 from $20 and keeps an Outperform rating on the shares. The firm notes the company announced a secondary offering and concurrent private placement with gross proceeds of $135M, alongside additional LX2020 PKP2 data. Leerink says that shoring up the balance sheet ahead of pivotal FACM trial initiation and additional PKP2 data makes sense to the firm, and keeps the focus on Lexeo's data rather than any balance sheet overhang.
Guggenheim
Buy
initiated
$30
2025-10-15
Reason
Guggenheim
Price Target
$30
2025-10-15
initiated
Buy
Reason
Guggenheim initiated coverage of Lexeo Therapeutics with a Buy rating and $30 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lexeo Therapeutics Inc (LXEO.O) is -6.43, compared to its 5-year average forward P/E of -3.64. For a more detailed relative valuation and DCF analysis to assess Lexeo Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.64
Current PE
-6.43
Overvalued PE
-1.90
Undervalued PE
-5.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.32
Undervalued EV/EBITDA
-4.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LXEO News & Events

Events Timeline

(ET)
2025-11-05
07:39:04
Lexeo Therapeutics Announces Q3 Earnings Per Share of 33 Cents, Below Consensus Estimate of 44 Cents
select
2025-10-17 (ET)
2025-10-17
06:19:00
Lexeo Therapeutics Prices 15.625M Share Spot Secondary at $8.00
select
2025-10-16 (ET)
2025-10-16
16:33:52
Lexeo Reveals Offering of Common Stock and Warrants, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-04Globenewswire
Lexeo Therapeutics to Host Virtual Event on Managing PKP2-Associated Arrhythmogenic Cardiomyopathy
  • Virtual Event Announcement: Lexeo Therapeutics is set to host a virtual event on December 9 at 3 PM ET, focusing on the management of PKP2-associated arrhythmogenic cardiomyopathy, featuring Dr. Victoria Parikh from Stanford University to enhance clinical understanding of the condition.
  • Expert Participation: The session will center on managing PKP2-ACM, with Dr. Parikh providing valuable clinical insights as an expert in the field, which will help improve treatment strategies for cardiovascular diseases.
  • Investor Engagement Opportunity: Analysts and investors can register for the event via Lexeo's website, fostering interaction with the company and increasing awareness of its research and development progress.
  • Replay Availability: Following the event, a replay will be archived in the investor section of Lexeo's website, ensuring that stakeholders who could not attend live can access critical information, thereby enhancing company transparency and investor relations.
[object Object]
Preview
4.0
11-06Benzinga
Chardan Capital Reaffirms Buy Rating on Lexeo Therapeutics with $17 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders succeed in the markets.

  • Exclusive Stories: The platform provides exclusive stories generated by Benzinga reporters, enhancing the trading experience for its users.

[object Object]
Preview
9.0
10-21Newsfilter
Innovative Approaches to Address Challenging Medical Conditions Beyond Conventional Medications

  • Advancements in Gene Therapies: New FDA guidelines from October 2025 are promoting streamlined approval pathways for cell and gene therapies, focusing on targeted solutions for severe conditions that traditional pharmaceuticals cannot address, with the precision medicine market projected to grow significantly by 2034.

  • Avant Technologies' Strategic Shift: Avant Technologies is transitioning to a partnership-driven model, aiming to develop integrated healthcare solutions through joint ventures, particularly in diabetes treatment and age-related diseases, leveraging innovative biotechnology partnerships.

  • Lexeo Therapeutics' Progress: Lexeo Therapeutics is advancing its gene therapy LX2006 for Friedreich ataxia cardiomyopathy, with promising interim data supporting a potential accelerated approval pathway, while also planning a pivotal study in 2026.

  • Fractyl Health's Gene Therapy Results: Fractyl Health reported strong preclinical results for its obesity gene therapy candidate RJVA-002, showing significant weight loss in animal models, and is advancing its multi-modality strategy with plans for clinical trials in 2026.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lexeo Therapeutics Inc (LXEO) stock price today?

The current price of LXEO is 9.09 USD — it has increased 4.97 % in the last trading day.

arrow icon

What is Lexeo Therapeutics Inc (LXEO)'s business?

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

arrow icon

What is the price predicton of LXEO Stock?

Wall Street analysts forecast LXEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXEO is 19.57 USD with a low forecast of 13.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lexeo Therapeutics Inc (LXEO)'s revenue for the last quarter?

Lexeo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Lexeo Therapeutics Inc (LXEO)'s earnings per share (EPS) for the last quarter?

Lexeo Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, decreased -62.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lexeo Therapeutics Inc (LXEO)'s fundamentals?

The market is revising No Change the revenue expectations for Lexeo Therapeutics, Inc. (LXEO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 81.08%.
arrow icon

How many employees does Lexeo Therapeutics Inc (LXEO). have?

Lexeo Therapeutics Inc (LXEO) has 72 emplpoyees as of December 05 2025.

arrow icon

What is Lexeo Therapeutics Inc (LXEO) market cap?

Today LXEO has the market capitalization of 663.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free